JAK2V617F mutation detection in patients with clinical suspicion of myeloproliferative neoplasm without leukemic expression. Preliminary study.
DOI:
https://doi.org/10.18004/Keywords:
myeloproliferative disorders, JAK2V617F, ARMS-PCR, ParaguayAbstract
Myeloproliferative neoplasms are clonal disorders of the haematopoietic stem cell characterized by the myeloid progenitors proliferation in bone marrow. Polycythemia vera, essential thorombocythemia and primary myelofibrosis are deseases without a leukemic condition. JAK2V617F is the denomination of an acquired point mutation found in the Januskinase 2 gene and associated to these pathologies. The aim of this preliminary study was to determinate the presence of JAK2V617F mutation in patient with suspected myeloproliferative disorders without leukemic condition using ARMS-PCR in the Hematopathology and Molecular Genetics Laboratory of the Instituto de Investigaciones en Ciencias de la Salud. In 64% of patients (9/14 blood samples) the mutation was detected. Detection of this mutation is useful in differential diagnosis, prognosis and therapeutic, furthermore, the assay is easy to perform and interpret.
References
1. Swerdlow SH, Vardiman JW, Campo E, Harris NL, Jaffe ES, Pileri SA, et al., editores. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Cuarta Edición. Lyon: IARC; 2008. 439 p
2. Melo JV, Hughes TP, Apperley JF. Chronic Myeloid Leukemia.American Society of Hematology Education Program Book. 2003 Ene;(1):132–52.
3. Tefferi A, Skoda R, Vardiman JW. Myoloproliferative neoplasms: contemporary diagnosis using histology and genetics. Clinical Oncology. 2009 Nov;6:627–37.
4. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature. 2005 Abr;434:1144–8.
5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Abr;7:388–97.
6. Kralovics R, Passamonti F, Buser AS, Soon-Siong T, Tiedt R, Passweg JR, et al. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. New England Journal Of Medicine. 2005 Abr;352(17):1779–90.
7. Levine RL, Pardanani A, Tefferi A, Gilliand DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature. 2007 Sep;7:673–83.
8. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of tha JAK2 V617F mutation in chronic myeloproliferative disorders. BLOOD. 2005 Sep;106(6):1162–8.
9. Campbell PJ, Green AR. The Myeloproliferative Disorders. New England Journal Of Medicine. 2006 Dic;355(23):2452–66.
10. Chen Q, Lu P, Jones AV, Cross NCP, Silver RT, Wang YL. Consultation in Molecular Diagnostics: Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. JMD. 20079(2):272-276.
